On September 8, 2022 PharmaMar (MSE:PHM) reported that new data on Zepzelca (lurbinectedin) and Yondelis (trabectedin) will be presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) congress, which is being held in Paris from 9th to 13th September (Press release, PharmaMar, SEP 8, 2022, View Source [SID1234619228]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Two new posters of different studies with lurbinectedin will be presented during the congress. In the first poster, entitled "Synthetic control arm (SCA) analysis of lurbinectedin compared to the standard of care (SoC) among patients with Small Cell Lung Cancer (SCLC) previously treated with platinum-based chemotherapy," the authors conclude that lurbinectedin has potential benefit compared to SoC in the post-platinum setting of SCLC.

In the second poster, entitled "Real-world (RW) outcomes of second-line (2L) Small Cell Lung Cancer (SCLC) patients treated with lurbinectedin," the authors report that outcomes of patients treated with second-line lurbinectedin monotherapy in the RW setting are consistent with those found in the phase II clinical trial. Furthermore, they conclude that lurbinectedin provides an additional treatment option for relapsed SCLC patients, including those with platinum-sensitive disease.

Regarding trabectedin, three posters will be presented, among which those entitled "Trabectedin induces apoptosis regardless of acquired resistance to PARP inhibitors in BRCA2 mutant high grade ovarian cancer cell lines" and "Randomized phase II study of trabectedin/olaparib compared to physician’s choice in subjects with previously treated advanced or recurrent solid tumors harboring DNA repair deficiencies" stands out, in which new data on trabectedin, showing its activity on advanced/metastasic cancer with defective Homologous Recombination (HR) DNA repair are presented.

The former shows preclinical data, suggesting that some high grade ovarian cancer cell lines with BRCA2 mutation and resistant to PARPi could potentially be overcome with trabectedin. The latter shows interim analyses from a phase II clinical trial suggesting that trabectedin could enhance the effect of PARP inhibitors in HR-deficient cancers, i.e., in those patients in whom their body is unable to repair double-strand breaks in DNA. The study has successfully passed the interim analysis. The trial is expected to be completed in 2022.

Highlighted studies at ESMO (Free ESMO Whitepaper) 2022

Lurbinectedin:

TITLE LEAD AUTHOR PRESENTATION
Synthetic control arm (SCA) analysis of lurbinectedin compared to the standard of care (SoC) among patients with small cell lung cancer (SCLC) previously treated with platinum-based chemotherapy Devon J. Boyne (Calgary, Canada) PRESENTATION NUMBER: 1536P FECHA: Saturday, September 10, 2022
Real-world (RW) outcomes of second-line (2L) small cell lung cancer (SCLC) patients treated with lurbinectedin Adina Estrin (New York, United States of America) PRESENTATION NUMBER: 1539P FECHA: Saturday, September 10, 2022
Trabectedin:

Trabectedin for patients with advanced soft tissue sarcoma: a non-interventional, prospective, multicenter study Viktor Grünwald (Essen, Germany) PRESENTATION NUMBER: 1496P FECHA: Sunday, September 11, 2022
Trabectedin induces apoptosis regardless of acquired resistance to PARP inhibitors in BRCA2 mutant high grade ovarian cancer cell lines Jose Alejandro Perez Fidalgo (Valencia, Spain) PRESENTATION NUMBER: 585P FECHA: Sunday, September 11, 2022
Randomized phase II study of trabectedin/olaparib compared to physician’s choice in subjects with previously treated advanced or recurrent solid tumors harboring DNA repair deficiencies Christoph E. Heilig (Heidelberg, Germany) PRESENTATION NUMBER: 487P FECHA: Monday, September 12, 2022